<SEC-DOCUMENT>0001193125-14-332098.txt : 20140904
<SEC-HEADER>0001193125-14-332098.hdr.sgml : 20140904
<ACCEPTANCE-DATETIME>20140904160600
ACCESSION NUMBER:		0001193125-14-332098
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20140904
ITEM INFORMATION:		Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20140904
DATE AS OF CHANGE:		20140904

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INOVIO PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001055726
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				330024450
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14888
		FILM NUMBER:		141083289

	BUSINESS ADDRESS:	
		STREET 1:		10480 WATERIDGE CIRCLE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		858 597-6006

	MAIL ADDRESS:	
		STREET 1:		10480 WATERIDGE CIRCLE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INOVIO BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20050404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20011116

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL LTD
		DATE OF NAME CHANGE:	19980213
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d782877d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section&nbsp;13 or 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>(Date of
earliest event reported) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>September&nbsp;4, 2014 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>INOVIO PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>001-14888</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>33-0969592</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>660 W. Germantown Pike, Suite 110</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Plymouth Meeting, Pennsylvania</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>19462</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: (267)&nbsp;440-4200 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former name or
former address, if changed since last report) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="12%" VALIGN="top" ALIGN="left"><B></B><U>Item&nbsp;3.01</U>.</TD>
<TD ALIGN="left" VALIGN="top"><U>Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing</U>.<B> </B></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) On September&nbsp;4, 2014, Inovio Pharmaceuticals, Inc. (the &#147;Company&#148;) provided notice to the NYSE MKT that the Company intends
to voluntarily transfer the listing of its common stock, par value $0.001 per share (the &#147;Common Stock&#148;), from NYSE MKT to the NASDAQ Global Select Market (&#147;NASDAQ&#148;). The Common Stock has been approved for listing on NASDAQ, and
the Company expects that the Common Stock will begin trading on NASDAQ on September&nbsp;15, 2014. The Common Stock will continue to trade under the ticker symbol &#147;INO.&#148; Until the transfer of the listing to the NASDAQ is completed, the
Common Stock will continue to be traded on NYSE MKT. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="12%" VALIGN="top" ALIGN="left"><B></B><U>Item&nbsp;7.01</U>.</TD>
<TD ALIGN="left" VALIGN="top"><U>Regulation FD Disclosure</U>.<B> </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;4, 2014, the Company issued a press
release announcing that it plans to transfer the listing of its Common Stock from the NYSE MKT to NASDAQ as detailed in Item&nbsp;3.01 above. A copy of the press release is furnished as Exhibit 99.1 to this report. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information contained in this Item&nbsp;7.01 and Exhibit&nbsp;99.1 to this report shall not be deemed to be &#147;filed&#148; for purposes
of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, and shall not be incorporated by reference into any filings made by the Company under the Securities Act of 1933, as
amended, or the Securities Exchange Act of 1934, as amended, except as may be expressly set forth by specific reference in such filing. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="12%" VALIGN="top" ALIGN="left"><B></B><U>Item&nbsp;9.01</U>.</TD>
<TD ALIGN="left" VALIGN="top"><U>Financial Statements and Exhibits</U>.<B> </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">Exhibits. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:23.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exhibit<BR>No.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:62.75pt; font-size:8pt; font-family:Times New Roman">Exhibit Description</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release dated September 4, 2014</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SIGNATURE </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">INOVIO PHARMACEUTICALS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Peter Kies</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Peter Kies,</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: September&nbsp;4, 2014 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-3- </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d782877dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g782877img001.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>NEWS RELEASE </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Immediate Release
</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="90%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>CONTACTS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investors:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">Bernie Hertel, Inovio Pharmaceuticals, 858-410-3101, <U>bhertel@inovio.com</U></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Media:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">Jeff Richardson, Inovio Pharmaceuticals, 267-440-4211, <U>jrichardson@inovio.com</U></TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Inovio Pharmaceuticals to List on NASDAQ </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PLYMOUTH MEETING, Pa. &#150; September&nbsp;4, 2014 &#150; Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that it has met the listing criteria
for the NASDAQ Global Select Market and will transfer its U.S. stock exchange listing from the NYSE MKT to the NASDAQ Global Select Market on September&nbsp;15, 2014. The company will retain its current ticker symbol, &#147;INO.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;J. Joseph Kim, President and CEO, said, &#147;The majority of our peers are listed on NASDAQ, the world&#146;s largest electronic stock market. We
expect this stock exchange will serve our investors well with respect to liquidity, pricing, speed of execution, and cost per trade. We also believe that the NASDAQ platform is an excellent vehicle for enhanced market visibility.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Inovio Pharmaceuticals, Inc. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Inovio is
revolutionizing the fight against cancer and infectious diseases. Our immunotherapies uniquely activate best-in-class immune responses to prevent and treat disease, and have shown clinically significant efficacy with a favorable safety profile. With
an expanding portfolio of cancer immunotherapies and clinical studies, the company is advancing a growing product pipeline. Partners and collaborators include&nbsp;Roche, the&nbsp;University of Pennsylvania, NIH, HIV Vaccines Trial
Network,&nbsp;National Cancer Institute, U.S. Military HIV Research Program,&nbsp;US Dept. of Homeland Security, and&nbsp;University of Manitoba.&nbsp;For more information, visit www.inovio.com. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* * * </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This press release contains certain
forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines and our capital resources. Actual events or results may differ from the expectations set
forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in
this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, including safety and efficacy for VGX-3100, that pre-clinical studies
and clinical trials may not commence or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be
indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA
vaccines, our ability to support our broad pipeline of SynCon<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> active immune therapy and vaccine products, the adequacy of our capital resources, the availability or potential availability of
alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to
develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the </I></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>
company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others
or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company&#146;s
technology by potential corporate or other partners or collaborators, capital market conditions including the trading market for our common stock on the NASDAQ Global Select Market, the impact of government healthcare proposals and other factors set
forth in our Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2013, our Form 10-Q for the quarter ended June&nbsp;30, 2014, and other regulatory filings from time to time. There can be no assurance that any product in
Inovio&#146;s pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided
herein will be proven accurate. </I></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g782877img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g782877img001.jpg
M_]C_X``02D9)1@`!`0$!+`$L``#_X@Q824-#7U!23T9)3$4``0$```Q(3&EN
M;P(0``!M;G1R4D="(%A96B`'S@`"``D`!@`Q``!A8W-P35-&5`````!)14,@
M<U)'0@``````````````````]M8``0````#3+4A0("``````````````````
M`````````````````````````````````````````````!%C<')T```!4```
M`#-D97-C```!A````&QW='!T```!\````!1B:W!T```"!````!1R6%E:```"
M&````!1G6%E:```"+````!1B6%E:```"0````!1D;6YD```"5````'!D;61D
M```"Q````(AV=65D```#3````(9V:65W```#U````"1L=6UI```#^````!1M
M96%S```$#````"1T96-H```$,`````QR5%)#```$/```"`QG5%)#```$/```
M"`QB5%)#```$/```"`QT97AT`````$-O<'ER:6=H="`H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0``9&5S8P`````````2<U)'0B!)14,V,3DV
M-BTR+C$``````````````!)S4D="($E%0S8Q.38V+3(N,0``````````````
M````````````````````````````````````````````````````6%E:(```
M`````/-1``$````!%LQ865H@`````````````````````%A96B````````!O
MH@``./4```.06%E:(````````&*9``"WA0``&-I865H@````````)*````^$
M``"VSV1E<V,`````````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```````````
M````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```````````````````````````
M``````````````````````````````````!D97-C`````````"Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92`M('-21T(`````````
M`````"Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92`M
M('-21T(`````````````````````````````9&5S8P`````````L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0``````````
M````+%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$``````````````````````````````````'9I97<``````!.D_@`47RX`
M$,\4``/MS``$$PL``UR>`````5A96B```````$P)5@!0````5Q_G;65A<P``
M```````!`````````````````````````H\````"<VEG(`````!#4E0@8W5R
M=@````````0`````!0`*``\`%``9`!X`(P`H`"T`,@`W`#L`0`!%`$H`3P!4
M`%D`7@!C`&@`;0!R`'<`?`"!`(8`BP"0`)4`F@"?`*0`J0"N`+(`MP"\`,$`
MQ@#+`-``U0#;`.``Y0#K`/``]@#[`0$!!P$-`1,!&0$?`24!*P$R`3@!/@%%
M`4P!4@%9`6`!9P%N`74!?`&#`8L!D@&:`:$!J0&Q`;D!P0')`=$!V0'A`>D!
M\@'Z`@,"#`(4`AT")@(O`C@"00)+`E0"70)G`G$">@*$`HX"F`*B`JP"M@+!
M`LL"U0+@`NL"]0,``PL#%@,A`RT#.`-#`T\#6@-F`W(#?@.*`Y8#H@.N`[H#
MQP/3`^`#[`/Y!`8$$P0@!"T$.P1(!%4$8P1Q!'X$C`2:!*@$M@3$!-,$X03P
M!/X%#04<!2L%.@5)!5@%9P5W!88%E@6F!;4%Q075!>4%]@8&!A8&)P8W!D@&
M609J!GL&C`:=!J\&P`;1!N,&]0<'!QD'*P<]!T\'80=T!X8'F0>L![\'T@?E
M!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".<(^PD0"24).@E/"60)>0F/":0)
MN@G/">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<"O,+"PLB"SD+40MI"X`+F`NP
M"\@+X0OY#!(,*@Q##%P,=0R.#*<,P`S9#/,-#0TF#4`-6@UT#8X-J0W##=X-
M^`X3#BX.20YD#G\.FPZV#M(.[@\)#R4/00]>#WH/E@^S#\\/[!`)$"800Q!A
M$'X0FQ"Y$-<0]1$3$3$13Q%M$8P1JA')$>@2!Q(F$D429!*$$J,2PQ+C$P,3
M(Q-#$V,3@Q.D$\43Y10&%"<4211J%(L4K13.%/`5$A4T%585>!6;%;T5X!8#
M%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@;&$`891B*&*\8U1CZ&2`9
M11EK&9$9MQG=&@0:*AI1&G<:GAK%&NP;%!L[&V,;BANR&]H<`APJ'%(<>QRC
M',P<]1T>'4<=<!V9'<,=[!X6'D`>:AZ4'KX>Z1\3'SX?:1^4'[\?ZB`5($$@
M;""8(,0@\"$<(4@A=2&A(<XA^R(G(E4B@B*O(MTC"B,X(V8CE"/"(_`D'R1-
M)'PDJR3:)0DE."5H)9<EQR7W)B<F5R:')K<FZ"<8)TDG>B>K)]PH#2@_*'$H
MHBC4*08I."EK*9TIT"H"*C4J:"J;*L\K`BLV*VDKG2O1+`4L.2QN+*(LURT,
M+4$M=BVK+>$N%BY,+H(NMR[N+R0O6B^1+\<O_C`U,&PPI##;,1(Q2C&",;HQ
M\C(J,F,RFS+4,PTS1C-_,[@S\30K-&4TGC38-1,U336'-<(U_38W-G(VKC;I
M-R0W8#><-]<X%#A0.(PXR#D%.4(Y?SF\.?DZ-CIT.K(Z[SLM.VL[JCOH/"<\
M93RD/.,](CUA/:$]X#X@/F`^H#[@/R$_83^B/^)`(T!D0*9`YT$I06I!K$'N
M0C!"<D*U0O=#.D-]0\!$`T1'1(I$SD42155%FD7>1B)&9T:K1O!'-4=[1\!(
M!4A+2)%(UTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I-`DU*39--W$XE
M3FY.MT\`3TE/DT_=4"=0<5"[40914%&;4>92,5)\4L=3$U-?4ZI3]E1"5(]4
MVU4H5755PE8/5EQ6J5;W5T17DE?@6"]8?5C+61I9:5FX6@=:5EJF6O5;15N5
M6^5<-5R&7-9=)UUX7<E>&EYL7KU?#U]A7[-@!6!78*I@_&%/8:)A]6))8IQB
M\&-#8Y=CZV1`9)1DZ64]99)EYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E#:9II\6I(
M:I]J]VM/:Z=K_VQ7;*]M"&U@;;EN$FYK;L1O'F]X;]%P*W"&<.!Q.G&5<?!R
M2W*F<P%S77.X=!1T<'3,=2AUA77A=CYVFW;X=U9WLW@1>&YXS'DJ>8EYYWI&
M>J5[!'MC>\)\(7R!?.%]07VA?@%^8G["?R-_A'_E@$>`J($*@6N!S8(P@I*"
M](-7@[J$'82`A..%1X6KA@Z&<H;7ASN'GX@$B&F(SHDSB9F)_HIDBLJ+,(N6
MB_R,8XS*C3&-F(W_CF:.SH\VCYZ0!I!ND-:1/Y&HDA&2>I+CDTV3MI0@E(J4
M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY`
MGJZ?'9^+G_J@::#8H4>AMJ(FHI:C!J-VH^:D5J3'I3BEJ:8:IHNF_:=NI^"H
M4JC$J3>IJ:H<JH^K`JMUJ^FL7*S0K42MN*XMKJ&O%J^+L`"P=;#JL6"QUK)+
MLL*S.+.NM"6TG+43M8JV`;9YMO"W:+?@N%FXT;E*N<*Z.[JUNRZ[I[PAO)N]
M%;V/O@J^A+[_OWJ_]<!PP.S!9\'CPE_"V\-8P]3$4<3.Q4O%R,9&QL/'0<>_
MR#W(O,DZR;G*.,JWRS;+MLPUS+7--<VUSC;.ML\WS[C0.="ZT3S1OM(_TL'3
M1-/&U$G4R]5.U='65=;8UUS7X-ADV.C9;-GQVG;:^]N`W`7<BMT0W9;>'-ZB
MWRG?K^`VX+WA1.',XE/BV^-CX^OD<^3\Y83F#>:6YQ_GJ>@RZ+SI1NG0ZEOJ
MY>MPZ_OLANT1[9SN*.ZT[T#OS/!8\.7Q<O'_\HSS&?.G]#3TPO50]=[V;?;[
M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____VP!#``,"`@,"`@,#
M`@,#`P,#!`<%!`0$!`D&!P4'"@D+"PH)"@H,#1$.#`P0#`H*#A0/$!$2$Q,3
M"PX4%A02%A$2$Q+_VP!#`0,#`P0$!`@%!0@2#`H,$A(2$A(2$A(2$A(2$A(2
M$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A+_P``1"`!@`0L#
M`2(``A$!`Q$!_\0`'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`
MM1```@$#`P($`P4%!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*Q
MP152T?`D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA9
M6F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*S
MM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ
M_\0`'P$``P$!`0$!`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#
M!`<%!`0``0)W``$"`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1
M"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI
M:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZ
MPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1
M`Q$`/P#]"OCK\7?^%0>$EU"WM4O-0OIOL]E%(2$W[2Q9\<[0!T'7IQ7AGPJ_
M:V\1:EXSL--\<QZ?/I^J3I;K-;P&)[9W("MC)#+G&<\X.<\5[K\<_A&GQ?\`
M"<>G170LK^RG^T64[C*!]I4JX'.TACTY&`:\2^%?[(>N:/XOLM4\;W>FI9:;
M<+.EO:RF9KET.5!)5=JY`/KVI)@?6:Y(YI:0#`I:&`4445(!11130!11138!
M1114@%%%%4@"BBBDP"BBBD`444570`HHHJ0"F2R"*-G<A549)/0#UI],FC$T
M;(X#*XPP/<4T!\8>+/VR_%,WB.=_"5MIEKI$$F(8KF`RO.@Z,QW#&>N%Q@'J
M:^H/A-\18?BCX)LM>MX/LKS%H[B#.?+E0X8`]QT(/H:^:/$_[%WB-?$4H\*:
MAI,VCW$K-$UW(T<ENI/W64*0V,X!'I7TQ\*/AU;_``N\%V6@VDK7+0;GGG(Q
MYLKG+,!V&>`/050'8T445+`****0!1115=`"BBBI`**\V_:+NY[#X-^([BQG
MFMIXXHBLL+E&7]ZG0@@BOEW]F'Q+K&I?&G1+?4=6U2Z@>&YW137;R(2(7QP3
M5(#[KHI!7SG^VCJ]]I'ACPZVE7MY9/)?R!VMIVC+#9T.#3`^C:KW-];V<?F7
M<\$"#JTL@48^IKX*^%OQ\U+X<Z+XEEFN;W5=6U".&+35O9WECA(\PO(<GH,K
MP.IQ[UB-X?\`B+\7[B35VL/$.OB9C_I#1-Y0]E)PH'LM*P'Z%66N:=J1QIU_
M971](9U?^1J]7YBZWX5\1>`[R(Z[INJ:).3^Y>6)HBQ_V6Z'\*^D_P!F+]H'
M4=9U>/PIXXNS>23I_P`2R\F8F0L.3$Q_B^4$@GGC'/&78#ZGHI`<]*`<TF`M
M)N%-+C)'I7CGC_XT:HAN+#X665A>RV[M%=Z_JLQBTVR=>J@K\]Q(#QMC&`>&
M8'BJI4Y5':/WF=2HH+4]B>54SN(``R2>U9\_B;2;9PESJ>GQ.3PKW2*?R)KX
MD\5^$O$'Q%N6?QQXX\<^+,G(L]$C72[)?8(-VX>YYKS_`,0_LP:;]F9H=`\7
M6DA'^M:\28_CF/\`K7HT\-@E_$K._E%M?>VOR.*I7QF].BK><E?\+GZ3P7T%
MTNZVFAF7L8W#?RJ;//2OR!U#P/XL^&MS]L\%:SK-O-;MG%M-):SI^"M\WX'\
M*]<^#?\`P4"\6>$[Z&P^*J'Q-I'"-=JBQ7D`S@GC"R8]#AO<GKV_ZORK4G4P
ME55$NFS^XX7GBHU%3Q=-P;Z[K[S](P<TM<_X)\<:)\0_#-GKW@_4(-2TR^3=
M%-$<X/=6'56!X(/(KS#]J[PSJ>H>`!KOAV]OK2Z\/2&6<6MR\1DMVP'^Z>=O
MRM]`:\!P<6U)69[L9*233NCV^BOA#]G'XLZGX>^*%A;Z_J=[=:;K7^A2BZO'
ME6)V/[MAN/'S`#Z,:^[L\TGL4+117A7[6?Q*E\&^!8=)T>=X-3U^7RP\<A1X
MX$(,C`CD$_*N?]HT(#W6BOAK]F;3=>\??$JVDO\`6=7ETS0@+R[5[Z5@Y'$:
M'+8(+<_137W(<]J-`%HK\\_C3XJURU^+/BN"SUC5H(8M4E6...]D55'H!NXK
M[D^%TTMQ\-_"TMS(\LLFCVK.[L6+,8ER23U-,#J***\O^-?QTTKX1::BNJW^
MMW:$VE@KXXZ;Y#U5,_GVJ>H'IS.$!+$*!U).,51D\0:9%+Y4NI6"2=T:X0-^
M6:_/'QG\7?&?Q.OU35]3O)8Y9,0Z=8EDBYZ*L:_>/UR?>H8O@EX_N;?[2OA'
M7F0C/S6C*Q_X">?TIV`_2"*>.9=T3HZ^JMFI*_-/1O%_C'X8:MML+W6-#O(C
ME[:?>@8#LT;C##\*^M/@-^TM:?$>:/1/%2PZ=XAV?NBIQ%??[@).'X)*\^Q[
M4,#WBBBBI`\P_:6_Y(EXG_ZX1?\`HY*^4?V5/^2Y:%_UQNO_`$2]?5W[2W_)
M$O$__7"+_P!')7RC^RI_R7+0O^N-U_Z)>K`^_:^9_P!N+_D5O#7_`&$)?_1=
M?3%?,_[<7_(K>&O^PA+_`.BZ`/"OV>/AU#\2?B1:6>J+OTS3HS>WJ9/[Q$("
MI^+,,^P-?H/;6D-G`D-K%'##$H5(XT"JJCH`!P!7R1^PY;JVO^*IR,O'9VZ*
M?0%W)_D*^O:38'-_$#P78^/?"FHZ+J\4<D5U"1&Y4$Q28^5U/8@X-?G+X<U.
M?PIXNT^^B(6XTC4(Y/\`@22#(^G!K]/3TK\O/%7'BK6-O&-0G_\`1AI@?J#$
MXDC5D^ZP!'TKBOB]\6-&^"_@:\\2^*"Q@MBL<%M$1YES*WW8TSW/)]@">U==
MI?\`R#+3_K@G_H(KX,_X*6^-)9-<\)>%('(M[>WDU&X4'[SLWEI^05_^^J]#
M*L$L9C(4I/1[^AY^:8MX7"3JK=;'4^#/V_;/XE>)K3PQK7A.XTB#7IUM;>Y@
MU'SOGD(5%D&U2%8D`E3QFOI/2OA=:74D5QXD"SF)0(;.(;((%[*$'&!7YD_L
MH^$G\4_&[P\8HS)_9=PMZ0!D;D8;#^!.?P%?KH@P!GKBN[B/"X7"8E4L.K*V
MOZ'%D&*Q&)P[J5W=WT(+32K.PC"65M!"JC`"(!4[PQRC$B(P/8KFGT5X*/=.
M!\>?!KP]XWLI$N;.*WN2#LGB&T@U^</[4'P/N_AKK1NQ"0DDNV1U'RN"<*_U
M['\*_5ROGC]N+PS::G\#=;U&X11-IT097/7EE`'YXKU,FQE3#XV#CU:37>YY
MN;8:G7P<U);)M>J/D#]A[XVWGPW^*5GX;O9Y&\.^+9UMI(7?Y8+DC$4JCL2<
M(?7</2OT^O[*'4K&>TO8UFM[F-HY8VZ.C#!!]B.*_#C3[^73-1MKRR8I<6\R
M2Q..J,K94C\<5^XFEW7V[3;6X8<SP(Y'U4'^M>UQ?A(4\1"M%:SO?Y6_S/%X
M3Q4ZE"=*3TC:WH[_`.1^;OQ,\%3_``X\=ZMH<P8+9S[K28'&^$X:-@?7!&?<
M'\/N_P"!_C]?B/\`#K2M5=@;Q(_LU\O<31\,?QX;_@5>2_MG_#K^TM"L/%NG
M0$SZ6PM[\H.3`Y^1C_NMD?\`;0UP?['?Q"&@^,[KPW?3E;37XPUNKG@7,8)P
M/]Y,C_@"U\B?6'VI7YW_`+0/Q`_X6)\3M2O+5]VG:?\`Z'9'.5,<9(+C_>;<
M?IM]*^O_`-HKXA+\/_AEJ%Q;3&/4=2'V.QV'Y@[@[G'^ZFX_@*^./@;X`/Q(
M^)&F:=+%YEA;O]JU`]O)3DC_`($<+_P*D@/KG]F'X>?\(/\`#.UN+V()J>ND
M7ER<8*H1^Z0_1>?JQKU^F11+#&J1@*J@``#``I]+J!^<'QN_Y+#XO_["LO\`
M2OO7X4_\DQ\)_P#8%M?_`$4M?!7QN_Y+#XO_`.PK+_2OO7X4_P#),?"?_8%M
M?_12U0&KXI\16OA+P[J6LZHQ6TTRUDN)<=2%&<#W/3\:_./6=5UOXM>/'N9=
MUWJ^OW8CMXBW"[FPD8/95&!]`37V5^UQJ\FE_!F^CA./[0O+>W?W7?O(_'9C
M\:^??V/=!AU3XN&YNT#MI.G37,&>TA98P?P5VI,#Z@^#WP2T3X5Z)"+>"*ZU
MJ9%-[J,B`N[XY5,_=3T`_&O2"H(QCB@#'2EHN!S'CSX<:#\1]&ET[Q39).CC
M]W.H`E@;LR/@X/Z>H-?GY\0/!>J?"+QU-I=Q.\=SI\J7-E=PDJ9$W9CE7T/'
MX$$5^E5?*G[;V@P+'X7UA$5;DM-:2,.K)A74?@=WYTP/;O@E\1%^)OP\TW5V
M(^V(OV:_7'2X0`.?H>&'LU=[7R[^P]K$DFG>*M+8DQ6\]O<H/0NK*W_HM:^H
MJ3`\P_:6_P"2)>)_^N$7_HY*^4?V5/\`DN6A?]<;K_T2]?5W[2W_`"1+Q/\`
M]<(O_1R5\H_LJ?\`)<M"_P"N-U_Z)>F!]^U\S_MQ?\BMX:_["$O_`*+KZ8KY
MG_;B_P"16\-?]A"7_P!%T`8/[#/.H^+O:&T'ZRU];5\D_L,?\A'Q?_UQM/YR
MU];4F`AZ5^7GBK_D:]9_["-Q_P"C&K]0STK\O/%7_(UZS_V$;C_T8U-`?IUI
M?_(,M/\`K@G_`*"*_.'_`(*+:?(GQ:TN_;)CFTP0`D="CEL?^/\`Z5^CVE_\
M@RT_ZX)_Z"*^5OVYOA.WC'P_;ZI:)F:U^Z^/N,/7V/(KU,FQD<)CH5)[;/YG
MF9QA98G!SIQWW7R/G_\`X)W:A90?&^[M;YD6:\T>3[*&.-[HZL0/?;N/_`:_
M3(<U^)GA+Q+K'PM\;Z?K>D@VFKZ'>"9$D!P2,@H1W5@2#[$U^LWP,^/?AOXY
M^&8M1\.7,<6H11J-1TN23]]9R$=".Z^C#@_7BO8XJP4W66*@KPDOR_S/)X:Q
MD/8O#RTDG^9Z=13=XSC/-&X#O7R2/J1U?(W_``48^($^@?"S2_#5LI!\47Q\
M^3;P(8-KE?J6*?@#7UE/<Q6Z.\\BQH@RS.<`#US7RY^T;X1B_:`TRTD\+P?V
MOI5DS>3<ABJS2`D,8#U8#&-X^4]B>:[LLJPH8J%>HKQB]3AS"E.MAYT8.TFK
M'Y[?#?PY+XM\>:+ID,9D%S>1>:`,XC4Y;]!C\:_:;18#:Z191/\`>C@13^`K
MY`_9L_9:D\*>)TU;4M->SC@.=T[%G?T&3VS7V6!@`#M7=G^;K'UH\B]V*T.3
M),KE@:#4W[S?_#&?XBT&S\4:'?:3J\9ELM1@>"=1U*L,''H>X]Z_-K5]+U3X
M8>.Y[4NT&IZ!J&8I2"`S(V4?Z$;6^AK]-J^2OVS_`(>^5>:;XPL$)6XQ9W^!
MG#`9B;VR`5_!:\0]D\U_:&^,*_%;6M'.G%AIVG6"'RL8`N9%5I?Q!PG_``$U
M]`_L@?#K_A&?`LNOZA"R:AXB8,FX<K;(2(_IN.6_$5\F_#/P3+\0_'6D:%`)
M-EY/_I+H,^7"OS.WY`_B17Z46%E#IME!:64:Q6]K$L42+T55&`/RH`G%+114
M]0/S@^-W_)8?%_\`V%9?Z5]Z_"G_`))CX3_[`MK_`.BEKX*^-W_)8?%__85E
M_I7WK\*?^28^$_\`L"VO_HI:H#C_`-J7P])X@^#&L_9@6DTUHKT`#.1&PW?^
M.EC^%?+O[+/C"+PK\7+!;Q@D&LQ/8,Y.`K.0R9^K(J_\"K[TOK&#4K2>TOHD
MGMKF,QRQN,AU8$$$?0U^=GQ?^&%_\(_&4MDXF%E(YFTN\!(#Q9RO(_C4X!^F
M>]`'Z-`Y`/2EKYI^#7[6.EWVFV^E?$VX&FZC;QA5U)P3#<@<#<1]U\=<\'KG
MM7O,'COPW=6HN;?Q!HDEN1D2K?Q%<?7=2:`W:^0?VV/%\5YK>A^';8AI-.B>
MZN,<[6DP$4^^%)_X$*]/^*/[5'A7P?83P^%KN#Q#K)!6**V<M#$W3=)(.,9[
M*23[=:^/M/L/$/QA\=^5$7U#6=;G+R2L#M3)Y9L=$4#\``*8'TU^Q)X?>U\+
M>(-:D'_(0O4MH^,96),D_G*1^%?2U<]X`\&VG@#PAIFA:8!Y=A`%>3&#+(>7
M<^[,2?QKH:E@<3\9O"=_XY^&^M:'H7D&^OXT6+SY"B9$BL<D`XX![5X7\#_V
M;?&'P\^)6F:[KYTDV5I'.K^1=%VR\3*.-H[D=Z]Q\:_$34/"VK)9V/@?Q=XB
MA:`2&[TJ.V,2DDC8?,F1MPQGICD5B?\`"ZM9Q_R2GXD?]^+'_P"2JZ(T*DE=
M+\482Q-.+LW^#/4P<^U>-?M*_"C7/BQH>C6GA8V7G6-T\LOVF8QC:5QQ@'/-
M:7_"ZM9[?"CXD?\`?BQ_^2J!\:M9[?"CXD?]^+'_`.2J?U:KV7WHGZW2[_@_
M\CF/V9_@OXB^$UYK\GBO^S]NI);K!]EN#)]PONSE1C[PKWNO*_\`A=6L@\_"
MCXC_`/?BQ_\`DJE_X75K/;X4?$C_`+\V/_R52>%J]E]Z#ZW2[_@_\CU(]*^)
M]<_9&\>ZAK>H7<']B>5=7DLJ;KT@[6<D<;..#7T+_P`+KUG_`*)1\2/^_%C_
M`/)5'_"ZM9[?"CXC_P#?BQ_^2J?U6KV7WH/K=+O^#_R/3+")H+&WBEQOCB56
MQTR!BJVMZ)::_I<]CJ<:S6]PNUE89KSS_A=6LC_FE'Q(_P"_%C_\E4?\+JUG
MM\*/B/\`]^+'_P"2J3PM5K5+[T'UNEW_``?^1\P?'[]DR6"XFN["UDN;/YC'
M/;C]Y$/0\<CV-?-5MX!\8?#[6XM1\%ZE<VNH6S?NY[><VLR8[')&1ZC)%?IC
M)\9=7F4I)\)OB*ZL.0UO8D?^E5<3XD;3O%!=K[X+?$&.5^KQ06*D_P#DS7KX
M+,<PPL/9QLX=FTU^9YF,P>`Q+YW=2[I-/\CP'P3^UK\>M)C2WU7PUIWBA`,>
M;+;>7(2/]N)PO_CM>@_\-,?'#7D$5GX)\%^&%E'-YK&HEPGOL5]Q_P"^35R3
MX?6'G!H/A;\4H5'4".Q_^2JW='T+3-)D#O\`"#XF7;`Y_?+9$?E]JHJ8J,M5
MAH)_UTN*E14$D\1-K^NMC'T;0_$/Q(O(S\1/$%[X^E1PZ:99VQL-&B;_`*:1
MK\UQCL)#CCD5]*^$_#4FE6R2:DRR76T*JH`J1*!PJKV`'%<'IWQ1O-'@$.F_
M"#X@V\8'W4M[$?\`MU5S_A=>LXR/A1\2.?\`IC8__)5>?6C7J[I?A;Y([Z57
M#TU[K?S3;^\]3``Z4M>5_P#"Z]9_Z)1\1_\`OS8__)5+_P`+JUK_`*)1\2/^
M_%C_`/)58?5:O9?>C7ZW2[_@_P#(]3KG?'_@^V\>>#M6T&_P(]2MRBR$9\MQ
MRC_@P!_"N-_X77K(_P":4_$C_OQ8_P#R52_\+IUH_P#-*/B1_P!^+'_Y*I_5
MJO9?>@^MTN_X/_(X+]DCX47/A:+6]>\10&/49+B33[=64CRTC?$A'J&<`9[A
M,]Z^D*\J'QIUA>!\)_B..<_ZBQ_^2J=_PNK6O^B4?$C_`+\6/_R52>%J]E]Z
M#ZW2[_@_\CU.D8X'%>6_\+KUG_HE'Q'_`._-C_\`)5)_PNO6?^B4?$?_`+\V
M/_R51]5J]E]Z#ZW2[_@_\CQ+XE?LM^-_%?Q`\0:SI0T?['J5_)-!YMX5;83Q
MD;3@_C7U'X%TBX\/>#-!TO4?+%UIVFP03"-MR[T15.#W&0:XG_A=>L_]$H^(
M_P#WYL?_`)*I?^%TZS_T2CXC_P#?FQ_^2J?U:KV_%!];I=_P?^1ZG7/>-_`6
MB_$30Y-*\56:W=L_*-T>)\<.C=5;W%<;_P`+KUG_`*)3\1_^_-C_`/)5)_PN
MO6?^B4?$C_OS8_\`R52^JU>WXH/K=+O^#_R/`/'?[&_B31[B6;P1=6^N698F
M."9Q!<(.P.?D;\Q]!7G3_L_?$2.4QMX1U/=G@HJD'_@0;'ZU]B?\+JUGO\*/
MB1_WXL?_`)*H_P"%U:S_`-$H^(__`'YL?_DJG]6J]E]Z#ZW2[_@_\CYK\(?L
MB^-?$$RG7TM?#UJ#EFN91+*1WPB=_JPKZL^%GP>\/_"K3#!H$+2WDZC[7?SX
M:6<CMGHJYZ*.*Q_^%U:R/^:4?$C_`+\6/_R50?C5K)_YI3\1_P#OS8__`"51
M]5J]E]Z#ZW2[_@_\CU,#`I:\UTCXM:MJFJ6=I/\`#;QYIL5U,(VN[N*S$4`/
M\;[;AFVCV!KTJL:E.4'9FT*D9JZ//_COX]N_AA\+M9\2Z0=.%W8&W6-M1S]G
MC\R>.,O)AE.U0Y8_,.E9'P2^*M]\1=0\3V%_<Z!KD'AZ:WCA\1>'"W]GW[2Q
MEVB3<\G[R+Y=X$C#]XG0D@=/\5_`9^)?@>^\/"Y%F+V6WD,QB\P+Y4Z2X*Y&
M0VS;U[UU=O;16L0CMHHX8UZ)&H4#\!4Z%G$?'/Q[=_"SX1^*O%NE16EQ=:!I
M[W44=V&,3%<</M(./H:XC7/VI/"]UXJ\!:'\.M<T37+OQ1XC33KZ$&1GAMC;
M3RM(G0;@\48YR,,>/3T/XO>`6^*/PU\0^%$O?[..NV36WVKRO-\K)!SMR,].
MF14'Q"^')\<ZEX)NUO?L8\'^(X]9V>4'^T[+>>'R\Y&W_7[L\_=QCF@#M=ON
M?SKQWXQ?'EOAGXJT/3-/L(M1M(2M_P"+;EI"/[&TEI!`MR<=_.=6P?\`EG#.
M?X17L?:O%YOV6_"OBC6/%.L?%*W'BK5O%-U()96EFMHXK`#9!9B-),&-$SG/
MWF>1N-V*-`/9(76>)71@RN,JRG@CUKR;X]_%?4OAIJ'@FTTG5/"FAP^)]5N+
M2[U3Q*KFVM4BM)IP<B:(`LT2J,MCYNAKM?AAX3O_``)X%TKP_K&JG6I='B-M
M!>M$8W>W5B(`^6.YUBV*S9^8J6P,USWQ>^"FF_&&]\,#Q*89]*T.ZNY+NPEA
MWB\2>SEMBH;(*%?-WAAD@KQ@X(-`-'X,>.[SXF?#O3?$6K6"Z=/>O.@6)F,5
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M].2HZ**]QTV"YMM.M8;^=;FYB@1)Y@FT2.``S`9XR<G%&@'GWQT^*6H?#/PY
M:KX-TC_A)/%^MW0M="T7?L^V.JF24L_\*K"DC;CQD*/XA77^"_%EAX[\+:3K
M^A2-)I^L6<=U;EN&"L`=K#LP.00>0017$>+/@'I7Q$^([^)?B%-+J]G9::EE
MH>F)++;+IQ9BUQ-OC<%GE_=*>F%B`YS6K\)/A3!\(;76M(\/W/\`Q3-SJ+WF
MD:<P9FTT2@--$)&8ET,V^09QCS".0!3`O?%'Q]_PKGPNVI06+ZK?W-W;6&F:
M>LWE&\N[B4111ER"$7<P+-@X4,<'&#G^'K;XGPZW;2^*;_P-=:5,3]JM+"PN
MH)K4;3CRYGE<3$-M!S''D9/'2MKXB>`[/XC>&;C1M3FNK0/)%/;7EHP6>SN(
MI%DAGC)!`=)$5AD$'&"""0>?\->&OB9:ZOIQ\6>,_#E_I5B6\]+'PX]M<Z@-
MI"B1VN'1,$ACL09(XP.*E@>B@9&<G\Z^<O!W[0NJ^*/BAK7A^_\`%7@#2DTO
MQ9=:-!HDVEW+ZA<PPOM5A,+@1AW'(_=D#'2OHY1@5Y%X*^%_C;P)XGUM](\2
M>&)?#6O>);K69[.XT"8W:"=PSQ+.MT$X(X)C/TH0'K@&1R3^!KC_``?XPN_$
M/B[QWI-Y#!%;^%=6MK*U>,-NE22PMKDE\\$AYV'&.`.^2>Q7('S=:\JUKX9>
M,;#Q;XAUKX9>*M)TB/Q889=2MM6T9[[R;F*%(%G@9)H\$Q1Q@H^Y<H#W(+`Z
M#X,^-;OXC_#+0?$FK0V]M=ZK`\DL5MN$:D2,N%W$GHHZFL+]H'QAXO\`A]X(
MN/$?@.X\.!=-*?:[;5[":<S>9-'&NQHYH]F-[$Y#9XZ5U_PY\$VOPX\#Z-X9
MTR6:>VT:U6!)IL;YB.6=L8&68DD``#/%5?BOX%;XE>`=3\-QWGV`ZB8?](\K
MS/+\N9)/NY&<[,=>]&@&MX6AUN+1(%\9W>F7FK`MYTVFVCVL##<=NV-Y)&'R
MX!RYR<GCI7/>,_'%[X;^('P^T&S@MY+7Q;?7MO=R2[M\2PV4LZE,'&2T8!R#
MP3TZUW"C"@&N0\5^`CXF\<>"?$`O#;CP?=W=QY'E[OM/GVLD&,Y^7'F;NASC
M%&@'78XS\WYUXYHGCOQY\4QJ6I_#5O#.@>';'4[FPL[G7+">^FU-K>5H9952
M.:(11>:CJN2S-L)PN0#[(!@5Y%;?"7Q9X'U#4U^$?B?2--T/5[N>]?2=<TB2
M_2RN9Y#),]N\<\3!&=F;RVW*&8E2`=M`'J&CF^DTNU;75M4U$Q+]J6T=C$),
M#=L+`';G.,C.*P/BEXX'PY\#ZCK<5M_:%]$$@TVP\S:U]>2L([>!3V+R,BY[
M`D]`:W=`L[[3]%LK;6[X:G?PPJMS>"$0BXD`^9P@)"`G)VY..F37#_$KX-6/
MQ9\0>'Y/&<K77A_P_P"==1Z4C/%YU^P"13M(C@XC0RA5'\4F2?E%+J!?^#WQ
M#;XE^![74[^W6PUJTDDL-=T]<_Z#J$#>7<0C/.T."5)^\C*W0UI?$WQ)<^"O
MAQXJ\0Z;'%/=Z#HMY?P13Y*.\,+R*&`(.TE0#@YQ7-?#SX*6?PL\9:]?>";F
M2R\.>(+:%[C17+S!-0CRK72RNY;+Q>6C*?\`GDA!'-=;X_\`"_\`PF_@7Q%X
M<^T?9?[?TJZT\S[-_E>=$T>_&1G&[.,CI3T`=X'UJ;Q/X+T#6+U$BN-6TRVN
MY4BR%5I(E<A<\X!;O63\7?%6J^"/`&I:QX7L/[1U"V:%55H)+A8(WE5)+AXH
MOWDBQ(S2E$^9@A`(SD'PJ\,>)/!_A"RT7QGJVC:P^F00VMI/INFR60\F.-4&
M]7FEW/\`+DD$#GI6EXZT/6=?T$P>$-=;P]JT,\4\%V;5;F)]C`F*6,D%HW&5
M8*R-SD,*+`8'P=\877C?PN^HWOB'PEXG0W+)#J'AQ'CB90%^62)Y)&BE4D@K
MN/;(7I7H%>>?#/X;ZEX3UKQ)X@\5ZEI^HZ]XIE@:[.F6!LK6*.%"L:I&SNS-
/\SEI&8EL@<!17H=#`__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
